Cardiff Oncology, Inc.CRDFNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank79
3Y CAGR+93.2%
5Y CAGR+7.1%
Studio
Year-over-Year Change

Price-to-book ratio

3Y CAGR
+93.2%/yr
vs -6.0%/yr prior
5Y CAGR
+7.1%/yr
Recent acceleration
Acceleration
+99.2pp
Accelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
3 yr
Consecutive growthElevated
PeriodValueYoY Change
20254.14+66.0%
20242.49+162.9%
20230.95+65.2%
20220.57-65.6%
20211.67-43.0%
20202.93+189.2%
20191.01+37.9%
20180.73-55.5%
20171.65-48.5%
20163.21-